(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037836 A2

(51) International Patent Classification[7]: C07D 487/00

(21) International Application Number:
PCT/US2004/034219

(22) International Filing Date: 14 October 2004 (14.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/511,712 15 October 2003 (15.10.2003) US

(71) Applicant *(for all designated States except US)*: **OSI PHARMACEUTICALS, INC.** [US/US]; 58 South Service Road, Suite 110, Melville, NY 11747 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BECK, Patricia, Anne** [US/US]; 20491 Hartford Road, Dixon, MO 65459 (US). **CESARIO, Cara** [US/US]; 4 Oak Road, New City, NY 10956 (US). **COX, Matthew** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **DONG, Han-Qing** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **FOREMAN, Kenneth** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **MULVIHILL, Mark, Joseph** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **NIGRO, Anthony, Innocenzo** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **SAROGLOU, Lydia** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **STEINIG, Arno, G.** [DE/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **SUN, Yingchuan** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WENG, Qinghua** [CN/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WERNER, Douglas** [US/US]; 1 Bioscience Park Drive, Farmingdale, NY 11735 (US). **WILKES, Robin** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB). **WILLIAMS, Jonathan** [GB/GB]; Watlington Road, Oxford, OX4 6LT (GB).

(74) Agent: **NGUYEN, Kim, T.**; Osi Pharmaceuticals, Inc., 58 South Service Road, Suite 110, Melville, NY 11747 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,*

[Continued on next page]

(54) Title: IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS



(I)

(57) Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q^1 and R^1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

WO 2005/037836 A2

IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.